Immediate Placebo Effect in Parkinson’s Disease – Is the Subjective Relief Accompanied by Objective Improvement?Fregni F.a · Boggio P.S.b · Bermpohl F.a, c · Maia F.b · Rigonatti S.P.b · Barbosa E.R.b · Pascual-Leone A.a
aHarvard Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass., USA; bDepartments of Psychology, Psychiatry and Neurology, University of Sao Paulo, Sao Paulo, Brazil; cDepartment of Psychiatry and Psychotherapy, Charité Campus Mitte, University Medicine Berlin, Berlin, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: A recent well-conducted meta-analysis showed that placebo effect is associated with a possible small benefit for subjective outcomes, but has no significant effects on objective outcomes. Objective: Herein, we aimed to investigate the immediate effects of two different types of placebo [placebo pill and sham transcranial magnetic stimulation (TMS)] in Parkinson’s disease (PD) patients and compared them to the standard treatment (levodopa) in a proper randomized, double-blind, crossover clinical trial. Methods: PD patients received three different interventions on different days: levodopa, placebo pill, and sham TMS. The motor function was assessed using simple and choice reaction time, Unified Parkinson’s Disease Rating Scale (UPDRS), finger tapping, Purdue Pegboard test, time to button up, walking time and supination-pronation. The subjective motor function was measured by a visual analogue scale (VAS). Results: The results showed that there was a significant motor function in the motor function only after the treatment with levodopa, but not after treatment with placebo pills or sham TMS. However, patients reported a similar subjective improvement in motor function indexed by VAS following these three treatments. Conclusion: These results suggest that placebo interventions in PD may have an immediate subjective sensation of improvement but result in no significant objective motor changes compared with levodopa treatment. Although physiological changes are possible after a placebo intervention, our findings suggest that the acute placebo effect in PD may be the result of the subjective change in the motor rating only.
© 2006 S. Karger AG, Basel
- Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594–1602.
- Goetz CG, Leurgans S, Raman R, Stebbins GT: Objective changes in motor function during placebo treatment in PD. Neurology 2000;54:710–714.
- Goetz CG, Leurgans S, Raman R: Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early Parkinson’s disease. Mov Disord 2002;17:283–288.
- de la Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ: Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science 2001;293:1164–1166.
Strafella AP, Ko JH, Monchi O: Therapeutic application of transcranial magnetic stimulation in Parkinson’s disease: the contribution of expectation. Neuroimage, in press.
- Vase L, Robinson ME, Verne GN, Price DD: Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005;115:338–347.
- Evans D: Suppression of the acute-phase response as a biological mechanism for the placebo effect. Med Hypotheses 2005;64:1–7.
- Ruck A, Sylven C: ‘Improvement’ in the placebo group could be due to regression to the mean as well as to sociobiologic factors. Am J Cardiol 2006;97:152–153.
- McDonald CJ, Mazzuca SA, McCabe GP Jr: How much of the placebo ‘effect’ is really statistical regression? Stat Med 1983;2:417–427.
- Sturman MM, Vaillancourt DE, Metman LV, Bakay RA, Corcos DM: Effects of subthalamic nucleus stimulation and medication on resting and postural tremor in Parkinson’s disease. Brain 2004;127:2131–2143.
- Pascual-Leone A, Valls-Sole J, Brasil-Neto JP, Cohen LG, Hallett M: Akinesia in Parkinson’s disease. I. Shortening of simple reaction time with focal, single-pulse transcranial magnetic stimulation. Neurology 1994;44:884–891.
Bornke C, Schulte T, Przuntek H, Muller T: Clinical effects of repetitive transcranial magnetic stimulation versus acute levodopa challenge in Parkinson’s disease. J Neural Transm Suppl 2004;68:61–67.
- Fregni F, Simon DK, Wu A, Pascual-Leone A: Non-invasive brain stimulation for Parkinson’s disease: a systematic review and meta-analysis of the literature. J Neurol Neurosurg Psychiatry 2005;76:1614–1623.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
- Wassermann EM: Risk and safety of repetitive transcranial magnetic stimulation: report and suggested guidelines from the International Workshop on the Safety of Repetitive Transcranial Magnetic Stimulation, June 5–7, 1996. Electroencephalogr Clin Neurophysiol 1998;108:1–16.
- Muller T, Benz S, Przuntek H: Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 2000;181:98–103.
Spiro HM: Doctors, Patients, and Placebos. New Haven, Yale University Press, 1986.
- Turner JA, Deyo RA, Loeser JD, Von Korff M, Fordyce WE: The importance of placebo effects in pain treatment and research. JAMA 1994;271:1609–1614.
- Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, et al: A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Ann Neurol 2003;54:403–414.
- Benedetti F, Pollo A, Lopiano L, Lanotte M, Vighetti S, Rainero I: Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses. J Neurosci 2003;23:4315–4323.
- Allain H, Destee A, Petit H, Patay M, Schuck S, Bentue-Ferrer D, et al: Five-year follow-up of early lisuride and levodopa combination therapy versus levodopa monotherapy in de novo Parkinson’s disease. The French Lisuride Study Group. Eur Neurol 2000;44:22–30.
- Spiegel D, Kraemer H, Carlson RW: Is the placebo powerless? N Engl J Med 2001;345:1276.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.